!Important update: There’s a new process to get your prescription.Click here
About HEMANGEOL Treatment

An innovation
in the treatment of
infantile
hemangioma.

Clinically proven safety and effectiveness profile.

Mother with infant
Formulation

Specifically designed and formulated for babies.

HEMANGEOL is a clear, colorless to slightly yellow oral-dosing solution supplied in a 120 mL amber glass bottle with a child-resistant screw cap. A specific oral syringe and syringe adapter are provided with each bottle. The oral dosing syringe measures HEMANGEOL according to volume in milliliters (mL).

HEMANGEOL is available in strawberry-vanilla flavor.

Alcohol-free
Sugar-free
Paraben-free
HEMANGEOL bottle, carton, and oral dosing syringe
Clinical Data

How HEMANGEOL was discovered.

2007

Propranolol, the active ingredient in HEMANGEOL, has long been used as a beta-blocker to treat certain cardiovascular conditions in adults.

In 2007, Dr. Christine Léauté-Labrèze and her colleagues made an unexpected observation while caring for an infant with infantile hemangioma (IH). After the child developed cardiomyopathy, a complication associated with oral steroid treatment, propranolol was prescribed to address the heart condition. The medical team observed that the infant's hemangioma also began to shrink.

This important discovery led researchers to further study propranolol as a treatment for infantile hemangioma. Combined with the need for a therapy specifically developed and approved for infants, this work ultimately resulted in the development of HEMANGEOL.

A Clinically Proven Treatment for Infantile Hemangioma.

HEMANGEOL (propranolol hydrochloride) oral solution is clinically proven to effectively treat babies with proliferating (growing) infantile hemangioma that requires treatment with a medicine that spreads throughout the body.

Your doctor can explain risks associated with treatment, including low blood sugar (hypoglycemia), and common side effects. Talk to your doctor about questions you may have about the safety and efficacy of HEMANGEOL.

An international clinical trial found that:

  • 60%, 6 out of 10 babies on HEMANGEOL had their infantile hemangioma lesion “completely or nearly completely resolved” by 6 months of therapy versus only 4% of babies who received no treatment (n=101).1

    *Of patients on HEMANGEOL 3.4 mg/kg/day for 6 months who were considered successes, 10% required retreatment for recurrence of hemangiomas.

  • 88%, Nearly 9 out of 10 of the babies treated with HEMANGEOL showed improvement by 5 weeks, compared with 5% of babies who received no treatment (n=55).2

    *Based on independent-investigator assessment of telangiectasis, color, textural change, and distortion of anatomical landmarks or skin contours compared to baseline.

  • <2%, Less than 2 in 100 of babies given HEMANGEOL had to stop treatment due to adverse experiences, reflecting a well-established safety profile in infants.1
  • Well tolerated, The most common side effects (>10%) were sleep problems, worsening respiratory tract infections, diarrhea, and vomiting — most were mild and manageable with your doctor’s guidance.1

A second uncontrolled study in 23 patients with proliferating infantile hemangioma included:

  • Function-threatening infantile hemangioma
  • Infantile hemangioma in certain anatomical locations that often leave permanent scars or deformity
  • Large facial infantile hemangioma
  • Smaller infantile hemangioma in exposed areas
  • Severe ulcerated infantile hemangioma
  • Pedunculated infantile hemangioma (a hemangioma that sticks out from the skin on a small stalk)
  • Target lesions were resolved in 36% of patients by 3 months

HEMANGEOL was studied in a primary clinical trial of 460 babies with proliferating (growing) hemangiomas (excluding life-threatening infantile hemangioma, function-threatening infantile hemangioma, and ulcerated infantile hemangioma with pain and lack of response to simple wound care measures).

HEMANGEOL can cause serious side effects, including low blood sugar (hypoglycemia), especially if your child is not taking feedings, or is vomiting.

Please read additional Important Safety Information for HEMANGEOL

Journal of the American Academy of DermatologyJournal of the American Academy of Dermatology research letter: Prescribing propranolol for infantile hemangioma: Assessment of dosing errorsView the full article on jaad.org

Published Data

Dosing Errors for HEMANGEOL vs Generic Propranolol Hydrochloride

In a 2017, the Journal of American Academy of Dermatology published a letter to the editor, “Prescribing propranolol for infantile hemangioma: Assessment of dosing errors,” showing results from an institutional review board-approved survey comparing the propensity for dispensing and dosing calculation errors of HEMANGEOL (propranolol hydrochloride oral solution 4.28 mg/mL) versus generic propranolol hydrochloride oral solutions (4 mg/mL and 8 mg/mL) during the treatment of infantile hemangiomas.

The survey of 220 pediatric dermatologists and other physicians who treat infantile hemangioma found that medication dispensing and calculation errors are very common among physicians prescribing generic propranolol hydrochloride vs. HEMANGEOL.

Article Source: https://www.jaad.org/article/S0190-9622(16)31183-5/fulltext

References Prescribing errors with pediatric oral propranolol solutions. Reactions Weekly 1651, 12 (2017). https://doi.org/10.1007/s40278-017-29824-x

How to Use

How to Use HEMANGEOL.

A short overview of how to give HEMANGEOL to your baby. Always follow your doctor’s instructions.

  • Give HEMANGEOL exactly as your doctor tells you. The dose is based on your baby’s weight and may be adjusted as they grow—never change the amount without your doctor’s direction.
  • Give HEMANGEOL twice a day, once in the morning and once in the late afternoon, at least 9 hours apart.
  • Always use the oral dosing syringe provided with HEMANGEOL, and follow the detailed Instructions for Use to prepare and give each dose.
  • Give HEMANGEOL during or right after a feeding. It comes in strawberry-vanilla flavor, and if needed can be diluted in a small amount of milk or fruit juice in the bottle.
  • If your child spits up a dose or you’re not sure they got all of the medicine, do not give another dose—wait until the next scheduled one.

Getting Started

How to get HEMANGEOL.

Learn how Eton Cares can help your family access HEMANGEOL, including support with prescriptions, insurance, and financial assistance.

How to Get HEMANGEOL
Doctor consulting with father and baby

References

  1. HEMANGEOL Prescribing Information. Eton Pharmaceuticals.
  2. Léauté-Labrèze C, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735-746.
Important Safety Information

USE: HEMANGEOL (propranolol hydrochloride) oral solution is a prescription medicine used to treat proliferating infantile hemangioma (a type of birthmark) requiring treatment throughout the body.

WHO SHOULD NOT TAKE HEMANGEOL?: Do not give HEMANGEOL to your child if they were born early and are less than 5 weeks corrected age; weigh less than 4.5 lbs; have asthma or a history of breathing problems (bronchospasm); have certain heart conditions (such as slow heart rate, heart block, or heart failure); have very low blood pressure; have high blood pressure caused by a tumor on the adrenal gland, called “pheochromocytoma”; or are allergic to propranolol or any of the ingredients in HEMANGEOL.